Health Affairs This Week11 Jun 2021

Insights into FDA's controversial decision to approve a new Alzheimer's treatment drug

This week, the US Food and Drug Administration approved Aduhelm (aducanumab) to treat patients with Alzheimer's disease using an accelerated approval pathway.

The drug was approved on June 7, 2021, and the decision was quick to spark controversy. At least two members of a panel of outside advisors to the FDA from Mayo Clinic and Washington University resigned in protest over the drug's approval.

Clinical trials for the drug, which is manufactured by Biogen, showed a reduction in amyloid beta plaques. According to the FDA, that is "a hallmark finding in the brain of patients with Alzheimer's" and "is expected to lead to a reduction in the clinical decline of this...form of dementia."

But there remain concerns about the drug's side effects in addition to its price tag.

Health Affairs' Senior Editor Leslie Erdelack joins Deputy Editor for Special Content Rob Lott on this episode of Health Affairs This Week to discuss the approval and review outstanding questions, drug pricing, and whether pharmaceutical companies might look to old data for new drug approvals.

Related Links:

The FDA's Approval of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues and Stakeholders (Health Affairs Blog)
Limiting Coverage Based On Efficacy And Safety: A Path For Medicare Regarding The Alzheimer's Treatment Aducanumab (Health Affairs Blog)
The Search For Effective Alzheimer's Therapies: A Work In Progress (Health Affairs)

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(271)

Why Healthcare Costs Are Rising in America: The $9 Trillion Outlook for 2025 and Beyond

Health Affairs Publishing’s Jeff Byers welcomes Michael Chernew, professor at Harvard Medical School, back to the pod to discuss the recently released National Health Expenditures Projections for 2025...

26 Jun 20min

Medicaid Work Requirements: Who’s Affected and What’s at Stake

Health Affairs Publishing’s Jeff Byers welcomes Alison Barkoff of George Washington University to the pod to explore the evolving landscape of Medicaid work requirements. They break down who is impact...

12 Jun 19min

Will the Rural Health Transformation Fund Deliver?

Health Affairs Publishing’s Jeff Byers welcomes Sarah Jane Tribble of KFF Health News to the pod to discuss the Rural Health Transformation Fund, highlighting how it aims to improve infrastructure and...

5 Jun 17min

Inside CVS Caremark: The Role of PBMs in Drug Costs & Access | SPONSORED

THIS SPONSORED PODCAST EPISODE IS BROUGHT TO YOU BY CVS HEALTH.In this sponsored episode, James Margiotta, Chief Growth Officer at CVS Caremark, joins Health Affairs Publishing's Jessica Bylander to u...

3 Jun 25min

Will the Medicare ACCESS Model Spark the Next Health Tech Gold Rush?

Health Affairs Publishing’s Jeff Byers welcomes Andrew Rundle of the Columbia University Mailman School of Public Health to the pod to discuss his recent Forefront article about Medicare’s upcoming AC...

29 Mai 16min

Policy Changes Reshaping Family Caregiving

Welcome to a new, limited podcast series exploring major policy changes affecting older adults. This episode is part of our Age-Friendly Health series, which explores topics at the intersection of agi...

27 Mai 23min

Why Teens Are Turning to AI for Mental Health | Caroline Figueroa

Trigger Warning: This episode includes discussion of youth mental health challenges, including suicide and self-harm. Listener discretion is advised.Health Affairs Publishing’s Kathleen Haddad welcome...

22 Mai 20min